The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent
Open accessAbstract
The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a context where alternative pathways are less active is expected to aid clinical response by increasing replication stress. Here we describe the development of the clinical candidate 2 (AZD6738), a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics. Compound 2 was developed improving aqueous solubility and eliminating CYP3A4 time-dependent inhibition starting from the earlier described inhibitor 1 (AZ20). The clinical candidate 2 has favorable human PK suitable for once or twice daily dosing and achieves biologically effective exposure at moderate doses. Compound 2 is currently being tested in multiple phase I/II trials as an anticancer agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798
Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623
Ishiyama, T., Murata, M., & Miyaura, N. (1995) · The Journal of Organic Chemistry · doi:10.1021/jo00128a024 · Cited by 1,590
REDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
DNA Replication Stress as a Hallmark of Cancer
Macheret, M., & Halazonetis, T. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040424 · Cited by 823
Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Sulfoximines: A Neglected Opportunity in Medicinal Chemistry
Lücking, U. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302209 · Cited by 672
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
Biotransformation Reactions of Five-Membered Aromatic Heterocyclic Rings
Dalvie, D. K., Kalgutkar, A. S., Khojasteh-Bakht, S. C., Obach, R. S., & O'Donnell, J. P. (2002) · Chemical Research in Toxicology · doi:10.1021/tx015574b · Cited by 518
Frings, M., Bolm, C., Blum, A., & Gnamm, C. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.091 · Cited by 501
The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization
Pennington, L. D., & Moustakas, D. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01807 · Cited by 408
Fokas, E., Prevo, R., Pollard, J. R., Reaper, P. M., Charlton, P. A., Cornelissen, B., Vallis, K. A., Hammond, E. M., Olcina, M. M., Gillies McKenna, W., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.181 · Cited by 369
Kim, H., George, E., Ragland, R. L., Rafail, S., Zhang, R., Krepler, C., Morgan, M. A., Herlyn, M., Brown, E. J., & Simpkins, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2273 · Cited by 291
Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G., Brown, J., Lau, A., Pratt, G., et al. (2016) · Blood · doi:10.1182/blood-2015-05-644872 · Cited by 276
Self-citationVendetti, F. P., Lau, A., Schamus, S., Conrads, T. P., O’Connor, M. J., & Bakkenist, C. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6247 · Cited by 239
Self-citationTargeting the ATR-CHK1 Axis in Cancer Therapy
Rundle, S., Bradbury, A., Drew, Y., & Curtin, N. (2017) · Cancers · doi:10.3390/cancers9050041 · Cited by 231
Foote, K. M., Blades, K., Cronin, A., Fillery, S., Guichard, S. S., Hassall, L., Hickson, I., Jacq, X., Jewsbury, P. J., McGuire, T. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301859s · Cited by 214
Self-citationSirvent, J. A., & Lücking, U. (2017) · ChemMedChem · doi:10.1002/cmdc.201700044 · Cited by 213
Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway
Yazinski, S. A., & Zou, L. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-121415-121658 · Cited by 175
Min, A., Im, S., Jang, H., Kim, S., Lee, M., Kim, D. K., Yang, Y., Kim, H. J., Lee, K.-H., Kim, J. W., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0378 · Cited by 171
Self-citationSjögren, E., Westergren, J., Grant, I., Hanisch, G., Lindfors, L., Lennernäs, H., Abrahamsson, B., & Tannergren, C. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.05.019 · Cited by 168
Hollenberg, P. F., Kent, U. M., & Bumpus, N. N. (2008) · Chemical Research in Toxicology · doi:10.1021/tx7002504 · Cited by 167
Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
Dillon, M. T., Barker, H. E., Pedersen, M., Hafsi, H., Bhide, S. A., Newbold, K. L., Nutting, C. M., McLaughlin, M., & Harrington, K. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0239 · Cited by 141
Lumping of Whole-Body Physiologically Based Pharmacokinetic Models
Nestorov, I. A., Aarons, L. J., Arundel, P. A., & Rowland, M. (1998) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1023/a:1023272707390 · Cited by 132
McGinnity, D. F., Collington, J., Austin, R. P., & Riley, R. J. (2007) · Current Drug Metabolism · doi:10.2174/138920007780866799 · Cited by 128
Menezes, D. L. D., Holt, J., Tang, Y., Feng, J., Barsanti, P. A., Pan, Y., Ghoddusi, M., Zhang, W., Thomas, G., Holash, J. A., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0240 · Cited by 109
Cryo-EM structure of human ATR-ATRIP complex
Rao, Q., Liu, M., Tian, Y., Wu, Z., Hao, Y., Song, L., Qin, Z., Ding, C., Wang, H., Wang, J., et al. (2017) · Cell Research · doi:10.1038/cr.2017.158 · Cited by 106
Zask, A., Kaplan, J. A., Verheijen, J. C., Richard, D. J., Curran, K. J., Brooijmans, N., Bennett, E. M., Toral‐Barza, L., Hollander, I. J., Ayral‐Kaloustian, S., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901415x · Cited by 105
Sohlenius-Sternbeck, A.-K., Jones, C., Ferguson, D., Middleton, B. J., Projean, D., Floby, E., Bylund, J., & Afzelius, L. (2012) · Xenobiotica · doi:10.3109/00498254.2012.669080 · Cited by 103
Atkinson, A., Kenny, J. R., & Grime, K. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005579 · Cited by 99
Barlaam, B. C., Cosulich, S. C., Degorce, S. L., Fitzek, M., Green, S. A., Hancox, U. J., der Brempt, C. L., Lohmann, J.-J. M., Maudet, M., Morgentin, R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501629p · Cited by 95
Biotransformation and bioactivation reactions of alicyclic amines in drug molecules
Bolleddula, J., DeMent, K., Driscoll, J. P., Worboys, P. D., Brassil, P. J., & Bourdet, D. L. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.924962 · Cited by 93
Drugging ATR: Progress in the Development of Specific Inhibitors for the Treatment of Cancer
Foote, K. M., Lau, A., & Nissink, J. W. M. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.33 · Cited by 92
Self-citationTargeting ATR in cancer medicine
Sundar, R., Brown, J. S., Garces, A. I., & Yap, T. A. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.05.002 · Cited by 85
Jackson, S. P., & Helleday, T. (2016) · Science · doi:10.1126/science.aab0958 · Cited by 83
Scott, J. S., Birch, A. M., Brocklehurst, K. J., Broo, A., Brown, H. S., Butlin, R. J., Clarke, D. S., Davidsson, Ö., Ertan, A., Goldberg, K., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300310c · Cited by 77
Physiologically Based Pharmacokinetic (PBPK) Modeling of Disposition of Epiroprim in Humans
Luttringer, O., Theil, F., Poulin, P., Schmitt‐Hoffmann, A. H., Guentert, T. W., & Lavé, T. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10461 · Cited by 74
Mašič, L. P. (2011) · Current Drug Metabolism · doi:10.2174/138920011794520044 · Cited by 71
Safina, B. S., Baker, S. J., Baumgardner, M., Blaney, P. M., Chan, B. K., Chen, Y., Cartwright, M. W., Castanedo, G. M., Chabot, C., Cheguillaume, A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003747 · Cited by 66
Lu, Y., Knapp, M. S., Crawford, K. R., Warne, R. L., Elling, R. A., Yan, K., Doyle, M., Pardee, G., Zhang, L., Ma, S., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.006 · Cited by 49
Yap, T. A., Krebs, M., Postel-Vinay, S. C., Bang, Y., El-Khoueiry, A. B., Abida, W. M., Harrington, K. J., Sundar, R., Carter, L., Álvarez, E. C., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32607-7 · Cited by 48
Barlaam, B. C., Cosulich, S. C., Delouvrié, B., Ellston, R. P. A., Fitzek, M., Germain, H., Green, S. A., Hancox, U. J., Harris, C. S., Hudson, K., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.002 · Cited by 43
Dunne, V. L., Ghita, M., Small, D. M., Coffey, C. B. M., Weldon, S., Taggart, C. C., Osman, S. O. S., McGarry, C. K., Prise, K. M., Hanna, G. G., et al. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.06.025 · Cited by 39
Developability assessment of clinical drug products with maximum absorbable doses
Ding, X. Z., Rose, J. P., & van Gelder, J. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.02.003 · Cited by 37
Inoue, K., Fukuda, K., Yoshimura, T., & Kusano, K. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00129 · Cited by 34
Development of pharmacodynamic biomarkers for ATR inhibitors
Chen, T., Middleton, F. K., Falcon, S. C., Reaper, P. M., Pollard, J. R., & Curtin, N. J. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.012 · Cited by 31
Cited by
Targeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 836
Mäder, P., & Kattner, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00960 · Cited by 438
Ertl, P., Altmann, E., & McKenna, J. M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00754 · Cited by 429
DNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322
Ivy, S. P., Kunos, C. A., Arnaldez, F. I., & Kohn, E. C. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1657403 · Cited by 11
Metadata
- Authors
- Foote, K. M., Nissink, J. W. M., McGuire, T., Turner, P., Guichard, S., Yates, J. W. T., Lau, A., Blades, K., Heathcote, D., Odedra, R., Wilkinson, G., Wilson, Z., Wood, C. M., & Jewsbury, P. J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-10-22
- Volume
- 61
- Issue
- 22
- Pages
- 9889-9907
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2897726163
- Cited by
- 332
- References
- 48
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.